Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity

Can the glucagon-like peptide-1 receptor agonist semaglutide safely reduce glucose levels and body weight in patients with schizophrenia, prediabetes, and obesity?In this placebo-controlled randomized clinical trial of 154 patients with schizophrenia, overweight or obesity, and prediabetes, 30 weeks of semaglutide, 1.0 mg/week, significantly lowered glycosylated hemoglobin A. Moreover, semaglutide reduced body weight by a mean value of 9.21 kg and improved physical quality of life without exerting negative mental health consequences.Semaglutide is safe and effective for lowering blood glucose and weight in patients with schizophrenia who also experience overweight or obesity and prediabetes.

Corresponding Author: Jan Frystyk, MD, PhD, DMSc, Department of Endocrinology, Odense University Hospital, Kløvervænget 6, 5000 Odense, Denmark (jan.frystyk@rsyd.dk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.